Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT03400332	TitleEstudio de BMS-986253 en combinación con nivolumab o nivolumab más ipilimumab en cánceres avanzados.	Fase Fase 2	Date Added 2018-01-17	Ubicación Arkansas, United States California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Bélgica Canadá Francia Alemania Italia Polonia España Suecia Suiza Reino Unido	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas BMS-986253, Ipilimumab, Nivolumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06322693	TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)	Fase Fase 1	Date Added 2024-03-21	Ubicación Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Corea, República de España	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03217747	TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	Fase Phase 1, Phase 2	Date Added 2017-07-14	Ubicación Texas, United States	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio	Etiquetas MSS/ MMRp
NCT ID NCT05141721	TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2021-12-02	Ubicación Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin	Etiquetas MSS/ MMRp
NCT ID NCT04104776	TitleUn estudio de CPI-0209 en pacientes con tumores sólidos y linfomas avanzados	Fase Fase 1	Date Added 2019-09-26	Ubicación Georgia, United States Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Francia Italia Corea, República de Polonia España Reino Unido	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas CPI-0209, CPI-0209	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05019534	TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2021-08-25	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf]	Etiquetas MSS/ MMRp
NCT ID NCT03981146	TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer	Fase Fase 2	Date Added 2019-06-10	Ubicación Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Nivolumab, Opdivo	Etiquetas MSS/ MMRp
NCT ID NCT04973163	TitleEstudio para probar diferentes dosis de BI 1823911 solo y combinado con otros medicamentos en personas con diferentes tipos de cáncer avanzado con mutación KRAS.	Fase Fase 1	Date Added 2021-07-22	Ubicación Texas, United States Bélgica España Reino Unido	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas BI 1701963, BI 1823911, Midazolam	Etiquetas MSS/ MMRp
NCT ID NCT03313778	TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors	Fase Fase 1	Date Added 2017-10-18	Ubicación Arizona, United States California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japón Reino Unido	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas mRNA-4157, Pembrolizumab, Keytruda	Etiquetas MSS/ MMRp
NCT ID NCT05308446	TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Fase Fase 2	Date Added 2022-04-04	Ubicación Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo	Etiquetas MSS/ MMRp

Showing 261 to 270 of 299 entries